Gemtuzumab Ozogamicin treatment represents a important breakthrough in the therapy of acute leukemic leukemia, particularly aggressive leukemic cancer (AML). This novel agent pairs a targeted protein directed for the https://www.targetmol.com/compound/gemtuzumab